Pleurectomy/decortication
Hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma after cytoreductive surgical procedures: a systematic review
World Journal of Surgical Oncology 2025 April 9 [Link] Hany Hasan Elsayed, Mohamed Elanany Elsaid Elanany, Mohamed Tarek ElSayegh, Aly Sherif Hassaballa, Mohammed Abdel-Gayed Abstract Surgery-based multimodality therapies for treatment of malignant pleural mesothelioma have been clinically explored in the past decades. In this regard, hyperthermic intrathoracic or intrapleural chemotherapy has been used as one…
Read MoreCytoreductive surgery in diffuse pleural mesothelioma. What have we learnt from MARS2, EORTC-L1205 and other recent studies?
European Journal of Surgical Oncology 2925 January 21 [Link] Loïc Lang-Lazdunski Abstract Cytoreductive surgery remains controversial in pleural mesothelioma. The MARS2 trial suggested that extended pleurectomy decortication following neoadjuvant chemotherapy was associated with no survival benefit, more serious adverse events and poorer quality of life than systemic chemotherapy alone in patients with resectable pleural mesothelioma.…
Read MoreRecurrence Patterns and Management after Pleurectomy Decortication for Pleural Mesothelioma
Annals of Surgery 2025 January 15 [Link] Juuso Paajanen, William G Richards, Yue Xie, Emanuele Mazzola, Kristina Sidopoulos, John Kuckelman, Ritu R Gill, Raphael Bueno Abstract Objective: We hypothesize that recurrence following pleurectomy decortication (PD) is primarily local. We explored factors associated with tumor recurrence patterns, disease-free interval (DFI), and post-recurrence survival (PRS). Summary background…
Read MoreSurgical indications for pleurectomy/decortication in pleural mesothelioma based on the newly revised 9th edition of the tumour-node-metastasis classification
Interdisciplinary Cardiovascular and Thoracic Surgery 2024 December 25 [Link] Masatoshi Kanayama, Masaru Takenaka, Takehiko Manabe, Katsuma Yoshimatsu, Rintaro Oyama, Hiroki Matsumiya, Masataka Mori, Koji Kuroda, Fumihiro Tanaka Abstract Objectives: The MARS2 trial questioned the efficacy of curative intent surgery for pleural mesothelioma (PM), while real-world clinical data from Japan suggest a favourable prognosis in surgical…
Read MoreSurgery for pleural mesothelioma in multimodality setting: comparison between surgical techniques in a high-volume centre
European Journal of Cardio-Thoracic Surgery 2024 November 28 [Link] Eleonora Faccioli, Andrea Dell’Amore, Giulia Lorenzoni, Marco Schiavon, Gianluca Canu, Giulia Pasello, Giovanni Zambello, Matteo Sepulcri, Viola Sambataro, Francesco Labella, Chiara Giraudo, Dario Gregori, Fiorella Calabrese, Federico Rea Abstract Objectives: Pleural mesothelioma (PM) is an aggressive disease linked to asbestos exposure, presenting significant treatment challenges. The…
Read MoreEpithelioid pleural mesothelioma successfully treated with perioperative immunotherapy: a case report
General Thoracic Cardiovascular Surgical Cases 2024 June 11 [Link] Gaku Yamazaki, Aki Fujiwara-Kuroda, Jun Muto, Hideki Ujiie, Masato Aragaki, Megumi Furuta, Sakurako Ohno, Kanako C Hatanaka, Yutaka Hatanaka, Yoshihiro Matsuno, Tatsuya Kato Abstract Background: Pleural mesothelioma, characterized by a dismal prognosis even with multimodal therapy, has seen emerging interest in immune checkpoint inhibitors (ICIs) due…
Read MoreEpithelioid pleural mesothelioma successfully treated with perioperative immunotherapy: a case report
General Thoracic and Cardiovascular Surgery Cases 2024 June 11 [Link] Gaku Yamazaki, Aki Fujiwara-Kuroda, Jun Muto, Hideki Ujiie, Masato Aragaki, Megumi Furuta, Sakurako Ohno, Kanako C Hatanaka, Yutaka Hatanaka, Yoshihiro Matsuno, Tatsuya Kato Abstract Background: Pleural mesothelioma, characterized by a dismal prognosis even with multimodal therapy, has seen emerging interest in immune checkpoint inhibitors (ICIs)…
Read MorePhase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and Design
Cancers 2024 October 4 [Link] Giulia Maria Stella, Daniela Lisini, Paolo Pedrazzoli, Giulia Galli, Chandra Bortolotto, Giulio Melloni, Gioacchino D’Ambrosio, Catherine Klersy, Amelia Grosso, Francesca Paino, Stefano Tomaselli, Laura Saracino, Giulio Alessandri, Augusto Pessina, Elena Grignani, Vittorio Rosti, Angelo Guido Corsico, Patrizia Comoli, Francesco Agustoni Abstract Background and rationale. Pleural mesothelioma (PM) is a rare…
Read MorePredictive potential of MRI in differentiating the predominant component in biphasic pleural mesothelioma
European Journal of Radiology 2024 May 26 [Link] Ritu R Gill, William G Richards, Hillary Heiling, Emanuele Mazzola, Yin P Hung, Ravi T Seethamraju, Lucian R Chirieac, Raphael Bueno Abstract Purpose: To assess the potential of apparent diffusion coefficient (ADC) values derived from diffusion weighted (DW) MRI preoperatively to predict the predominant histologic component among…
Read MoreExtended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial
The Lancet Respiratory Medicine 2024 May 10 [Link] Eric Lim, David Waller, Kelvin Lau, Jeremy Steele, Anthony Pope, Clinton Ali, Rocco Bilancia, Manjusha Keni, Sanjay Popat, Mary O’Brien, Nadza Tokaca, Nick Maskell, Louise Stadon, Dean Fennell, Louise Nelson, John Edwards, Sara Tenconi, Laura Socci, Robert C Rintoul, Kelly Wood, Amanda Stone, Dakshinamoorthy Muthukumar, Charlotte Ingle,…
Read More